Bayer Debuts Centafore Imaging Core Lab

Bayer has launched its Imaging Core Lab under the brand name Centafore. The lab is designed to be an imaging solution provider that offers tailored services for customers to support clinical trials and Software as a Medical Device (SaMD) development across diverse therapeutic areas and development phases.

Bolstered by Bayer’s quarter-century-plus experience in supporting more than 200 clinical trials, Centafore provides technology and services for image management, processing, and interpretation, empowering study sponsors with expert project management and facilitating advanced imaging data analyses. Its extensive network includes experienced imaging professionals such as board-certified radiologists, enabling customers to effectively manage studies across more than 50 countries.

“Centafore represents a significant leap forward in our commitment to enhancing the landscape of clinical trial imaging and advancing the development of new medicines and healthcare solutions,” Bayer Radiology President Nelson Ambrogio said. “By leveraging our experience and expertise, we are dedicated to providing our customers with high-quality imaging services that meet their specific needs in clinical research. Through Centafore, we aim to enhance the reliability of trial outcomes and support informed decision-making in the development of investigational medicines, ultimately benefiting patients and improving their quality of care.”

The services support numerous therapeutic areas, including oncology, cardiovascular, central nervous system (CNS), dermatology, women’s health, pediatrics, and digital health. It aims to help pharmaceutical, biotech, medical device and digital health companies with early research through Phase IV trials and SaMD development, and adherence to regulatory and data privacy compliance standards.

Centafore is already collaborating with organizations such as OBIO and Luxsonic Technologies to leverage clinical imaging as a critical tool for improving decision-making in clinical trials and software as a medical device development.

Building on a century of expertise, Bayer develops products and high-quality services in diagnostic imaging to enhance patient care. Its radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray, magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. Bayer’s radiology products generated €2.1 billion in 2024 global sales.

Bayer is a global enterprise with core competencies in healthcare and nutrition. The company drives sustainable development and generates a positive impact with its businesses. In fiscal 2024, the Group employed around 93,000 people and generated €46.6 billion in sales. R&D expenses amounted to €6.2 billion euros.